報價延遲最少15分鐘:2025/06/02 05:40 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7629 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.55/-187.84
|
|
企業價值
4.98M
|
| 資產負債 |
|
每股賬面淨值
0.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 05:40 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. |